Freenome Stock
Multiomics Platform for Early Disease Screening
Sign up today and learn more about Freenome Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Freenome Stock
Headquartered in South San Francisco, Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. Freenome aims to reinvent disease management through systematized early detection and intervention. Since launching in 2014, the company has raised more than $70 million from leading technology and healthcare investors.
Investors
Agent Capital
Allen & Company
Stripe, Relativity Space, Vroom, Joby Aviation, Convoy, Blend, Aspiration, Freenome, Bolt Threads, Turo
AME Cloud Ventures
Lacework, Wish, Eat Just, Zymergen, Illumio, Recursion Pharmaceuticals, Freenome, FiscalNote, Planet, Vectra
Andreessen Horowitz
Lyft, Robinhood, Databricks, Airbnb, Instacart, Stripe, Magic Leap, Anduril Industries, Rappi, CoinSwitch Kuber
Asset Management Ventures (AMV)
Bain Capital Life Sciences
BrightEdge Fund
Catalio Capital Management
Charles River Associates
Cormorant Asset Management
CRV
DoorDash, Airtable, Bird, Fair, Cybereason, Twitter, Niantic, ClassPass, Recursion Pharmaceuticals, Freenome
EcoR1 Capital
Fidelity Management and Research Company
goPuff, Nuro, Bolt, Caris Life Sciences, Relativity Space, Deliveroo, Farmers Business Network, Checkr, Freenome, Bowery Farming
Founders Fund
Lyft, SpaceX, Spotify, Airbnb, Stripe, Anduril Industries, Flexport, Palantir Technologies, Wish, Compass
GV
Uber, Robinhood, Jet, Impossible Foods, Lacework, Slack, Snyk, SambaNova Systems, DocuSign, Gusto
Innovation Endeavors
Plenty, Zymergen, Getaround, Freenome, Course Hero, Yotpo, HomeLight, Blockstream, fabric, Mark43
Janus Henderson Investors
Kaiser Permanente Ventures
Freenome, Proteus Digital Health, Vidyo, Everytable, Nuvolo, Ginger, Vesta Healthcare
Longevity Vision Fund
Loxbridge Research
Novartis
Perceptive Advisors
Zymergen, Freenome, Omada Health, Crossover Health, Twin Health, Emulate, PROCEPT BioRobotics, AEGEA Medical, Saama
Polaris Partners
Freenome, Automattic, Club Factory, OM1, Egnyte, Quartet, Impinj, VeraCode, Xant, Drizly
Roche Venture Fund
Rock Springs Capital
S28 Capital
Collective Health, Freenome, Aurora Solar, Outschool, CaptivateIQ, Mattermost, Kespry
Sands Capital Management
Section 32
Celularity, Freenome, Dialpad, Lime, Metromile, Primer, Vineti, Kobalt, BigHat Biosciences
Third Kind Venture Capital
T. Rowe Price
One97, Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Nuro, Caris Life Sciences, Vroom
Verily
Funding History
| October 2015 | $800K |
|---|---|
| June 2016 | $5.6M |
| August 2017 | $72.0M |
| June 2019 | $165M |
| July 2020 | $270M |
Management
Chief Executive Officer
Mike Nolan
Chief Financial Officer
William Quirk
Press
chinamoneynetwork - Aug, 28 2020
Cancer Screening Startup Freenome Raises $270Mcnbc - Feb, 1 2020
These start-ups are racing to help doctors detect cancer early with a simple blood testnanalyze - Oct, 8 2019
9 Genomics Startups for Investors to Watchbioportfolio - Jul, 24 2019
Freenome Closes $160 Million Series B Financing to Advance Its Multiomics Blood Testing Platform for Early Cancer Detectionbusinesswire - Jul, 12 2018
Freenome’s IMPACT Advisory Board Brings Strategic Insight and Real-World Experience to AI-Genomics Cancer Testsbusinesswire - Apr, 24 2018
Freenome and Biognosys Announce Collaboration to Improve Early-Cancer Detection and Treatmentbusinesswire - Mar, 29 2018
Institut Curie and Freenome Announce a Strategic Collaboration in Cell-Free DNA Analysis Using Machine Learning Technologyxconomy - Mar, 22 2018
Freenome Co-founder & Investor Chat Where Big Data Meets Big Bio on April 26wired - Jan, 17 2018
Startups Race to Create Cancer Screens from DNAfiercebiotech - Dec, 11 2017
FreenomeTechCrunch - Jul, 8 2017
These South Bay and Peninsula cities are raking in venture capitalnanalyze - Apr, 18 2017
8 Blood Tests for Cancer Being Developed by StartupsEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
